Completed OBSERVATIONAL NCT01216592

Airway Inflammation, Symptoms and Lung Function in COPD

Correlations Between Airway Inflammation, Symptoms and Lung Functions in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)

Sponsor: AstraZeneca

Conditions Chronic Obstructive Pulmonary Disease

Interventions COPD treatment

Updated 10 times since 2017 Last updated: Dec 4, 2011 Started: Jan 31, 2009 Primary completion: Jan 31, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01216592, this observational or N/A phase trial focuses on Chronic Obstructive Pulmonary Disease and remains completed. Sponsored by AstraZeneca, it has been updated 10 times since 2009, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed

▶ Show 5 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Università degli Studi di Ferrara

Data source: Università degli Studi di Ferrara

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ferrara, Italy